Clinical implementation of gene-silencing technologies has reached a definitive milestone as of January 2026, with the European Medicines Agency granting accelerated pathways for lipid-nanoparticle-delivered RNAi treatments. These precision interventions, specifically targeting the production of transthyretin proteins, are fundamentally altering the management of restrictive cardiomyopathies....